IP Library Granted Patent US 8,163,928
Granted Patent B2
US 8,163,928 · App. 12/162,255 · Granted Apr 24, 2012

Heteroaryl substituted benzothiazoles

Assignee: AstraZeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,928
App. No.
12/162,255
Granted
Apr 24, 2012
Kind
B2
Abstract

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Claims (24)

1. An optionally radiolabelled compound or salt thereof, wherein the compound corresponds to:

wherein:

one or more of the atoms is optionally replaced with a detectable isotope.

2. The compound or salt thereof according to claim 1 , wherein:

one to three of the atoms is/are a detectable isotope selected from 3 H, 19 F, and 13 C; or

one of the atoms is a detectable isotope selected from 18 F, 11 C, and 14 C.

3. The compound or salt thereof according to claim 1 , wherein one or more of the atoms is/are a detectable isotope selected from 3 H, 18 F, 19 F, 11 C, 13 C, 14 C, 75 Br, 76 Br, 120 I, 123 I, 125 I, and 131 I.

4. The compound or salt thereof according to claim 3 , wherein:

one atom is a detectable isotope, and

the detectable isotope is selected from 18 F and 11 C.

5. The compound or salt thereof according to claim 4 , wherein the compound corresponds to:

6. A compound, wherein the compound corresponds to:

7. A pharmaceutical composition, wherein the composition comprises:

a compound or salt thereof according to claim 1 , and

a pharmaceutically acceptable carrier.

8. A pharmaceutical composition for in vivo imaging of amyloid deposits, wherein the composition comprises:

a compound or salt thereof according to claim 3 , and

a pharmaceutically acceptable carrier.

9. A pharmaceutical composition for in vivo imaging of amyloid deposits, wherein the composition comprises:

a compound or salt thereof according to claim 4 , and

a pharmaceutically acceptable carrier.

10. A pharmaceutical composition for in vivo imaging of amyloid deposits, wherein the composition comprises:

a compound or salt thereof according to claim 5 , and

a pharmaceutically acceptable carrier.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 9, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 041518/0749 →
SECURITY INTEREST Recorded May 15, 2015
From: NAVIDEA BIOPHARMACEUTICALS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 035653/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2013
From: ASTRAZENECA AB
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 031296/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2008
From: GRAVENFORS, YLVA; JONASSON, CATRIN; MALMSTROM, JONAS; PYRING, DAVID; SOHN, DANIEL; NORDVALL, GUNNAR; SLIVO, CAN; STROM, PETER; WENSBO, DAVID
To: ASTRAZENECA AB
Reel/Frame 021303/0422 →
Continuity (2)
Provisional Application 60762654 · Jan 27, 2006
Related Publication 20090028787A1 · Jan 29, 2009